Safety and efficacy of intra-articular triamcinolone acetonide injection versus standard of care in patients with rheumatoid arthritis flare

نویسندگان

1 ChanRe Rheumatology and Immunology Center and Research, Bengaluru, India

2 Resident, ChanRe Rheumatology and Immunology Center and Research, Bengaluru, Karnataka

doi
10.32592/RR.2024.9.4.189
چکیده

Triamcinolone acetonide is a commonly used corticosteroid for rheumatoid arthritis (RA) flares, providing extendedrelief. However, there is limited data from controlled trials comparing the efficacy of intra-articular corticosteroid (IACS)injections to standard care, particularly with non-steroidal anti-inflammatory drugs (NSAIDs). This non-randomized,single-center, open-label study evaluated the safety and efficacy of IACS injections in RA patients experiencing kneejoint flare-ups. A total of 64 patients were screened and 44 received IACS (triamcinolone acetonide) and 15 wereincluded in the control group. Significant improvements were observed in the IACS group in pain, swelling, and morningstiffness at week 2, which were sustained through weeks 6 and 12. The swollen joint count significantly reduced byweek 12, while the tender joint count showed improvement by week 2. Pain reduction was substantial, as indicated bysignificant decrease in visual analog scale scores for pain, swelling, and mobility. The disease activity score-28 improvedsignificantly across all time points. In addition, the C-reactive protein level decreased significantly at week 2 and itsdecreasing trend continued until weeks 6 and 12. By week 2, all patients had ceased NSAID use. The study demonstratedthe effectiveness of IACS in reducing RA flare severity, particularly in terms of pain, swelling, and functionalimpairment, with no major safety concerns reported.